Becton Dickinson Receivables 2010-2024 | BDX

Becton Dickinson receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
  • Becton Dickinson receivables for the quarter ending June 30, 2024 were $2.596B, a 7.54% increase year-over-year.
  • Becton Dickinson receivables for 2023 were $2.534B, a 15.65% increase from 2022.
  • Becton Dickinson receivables for 2022 were $2.191B, a 6.77% decline from 2021.
  • Becton Dickinson receivables for 2021 were $2.35B, a 2% decline from 2020.
Becton Dickinson Annual Receivables
(Millions of US $)
2023 $2,534
2022 $2,191
2021 $2,350
2020 $2,398
2019 $2,345
2018 $2,319
2017 $1,744
2016 $1,618
2015 $1,618
2014 $1,187
2013 $1,240
2012 $1,250
2011 $1,229
2010 $1,205
2009 $1,169
Becton Dickinson Quarterly Receivables
(Millions of US $)
2024-06-30 $2,596
2024-03-31 $2,559
2023-12-31 $2,267
2023-09-30 $2,534
2023-06-30 $2,414
2023-03-31 $2,413
2022-12-31 $2,282
2022-09-30 $2,191
2022-06-30 $2,218
2022-03-31 $2,303
2021-12-31 $2,177
2021-09-30 $2,350
2021-06-30 $2,078
2021-03-31 $2,118
2020-12-31 $2,370
2020-09-30 $2,398
2020-06-30 $1,993
2020-03-31 $2,160
2019-12-31 $2,074
2019-09-30 $2,345
2019-06-30 $2,220
2019-03-31 $2,279
2018-12-31 $2,216
2018-09-30 $2,319
2018-06-30 $2,243
2018-03-31 $2,293
2017-12-31 $2,000
2017-09-30 $1,744
2017-06-30 $1,749
2017-03-31 $1,569
2016-12-31 $1,518
2016-09-30 $1,618
2016-06-30 $1,618
2016-03-31 $1,574
2015-12-31 $1,513
2015-09-30 $1,618
2015-06-30 $1,645
2015-03-31 $1,572
2014-12-31 $1,031
2014-09-30 $1,187
2014-06-30 $1,204
2014-03-31 $1,130
2013-12-31 $1,113
2013-09-30 $1,240
2013-06-30 $1,255
2013-03-31 $1,220
2012-12-31 $1,168
2012-09-30 $1,250
2012-06-30 $1,160
2012-03-31 $1,238
2011-12-31 $1,139
2011-09-30 $1,229
2011-06-30 $1,250
2011-03-31 $1,210
2010-12-31 $1,093
2010-09-30 $1,205
2010-06-30 $1,090
2010-03-31 $1,142
2009-12-31 $1,075
2009-09-30 $1,169
2009-06-30 $1,145
2009-03-31 $1,062
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $66.939B $19.372B
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $66.345B 18.25
Cardinal Health (CAH) United States $26.957B 14.91
West Pharmaceutical Services (WST) United States $22.428B 43.73
Cooper (COO) United States $22.013B 31.33
Labcorp (LH) United States $19.078B 15.89
Align Technology (ALGN) United States $18.899B 36.51
Henry Schein (HSIC) United States $9.181B 16.81
Merit Medical Systems (MMSI) United States $5.746B 30.37
DENTSPLY SIRONA (XRAY) United States $5.414B 14.52
CONMED (CNMD) United States $2.343B 20.38
Patterson (PDCO) United States $1.936B 10.21
STAAR Surgical (STAA) United States $1.544B 69.76
Lifevantage (LFVN) United States $0.127B 17.48
Pro-Dex (PDEX) United States $0.086B 41.13